Advances in the treatment of Alzheimer's disease

Pharmaceutical Journal

Volumn 259, Issue 6966, 1997, Pages 693-696

  Paton, Carol ^a   Branford, David ^b  

^a Bexley Hospital   (United Kingdom)

^b Fosse Health Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMPHETAMINE; AMYLOID PRECURSOR PROTEIN; ARECOLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETHANECHOL; CHELATING AGENT; CHOLINE; CHOLINESTERASE INHIBITOR; DEFEROXAMINE; DIGOXIN; DIHYDROERGOTOXINE MESILATE; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; METRIFONATE; NAFTIDROFURYL OXALATE; NALTREXONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE ANTAGONIST; PHOSPHATIDYLCHOLINE; PILOCARPINE; PIRACETAM; RIVASTIGMINE; SELEGILINE; TACRINE; THIAMINE; VASODILATOR AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CHOLINERGIC ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LEWY BODY; MENTAL HEALTH; NEUROFIBRILLARY TANGLE; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PROTEIN METABOLISM;

EID: 0030710453     PISSN: 00316873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American Psychiatric Association. Practice guidelines for the treatment of Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154:5(suppl)1-39.
2. Rossor M. Alzheimer's disease. BMJ 1993;307:779-82.
3. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of the Lewy body type. Ibid 1992;305:673-8.
4. Prusiner SB. Genetic and infectious prion diseases. Arch Neurol 1993;50:1129-53.
5. Sneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: A selective review. Int J Geriet Psychiatry 1991;6:691-708.
6. Jagger C, Clarke M, Anderson J. Misclassification of dementia by the mini-mental state examination: are educational and social class the only factors. Age Ageing 1992;21:404-11.
7. Whalley LJ. Drug treatments of dementia. Br J Psychiatry 1989;155:595-611.
8. Knapp MJ, Knopman DS, Soloman PR, Pendlebury WW, Davis CS, Gracon SI. A 30 week randomised controlled trial of high dose tacrine in patients with Alzheimer's disease. J Am Med Assoc 1994;271:985-91.
9. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;345:704-6.
10. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. AmJ Psychiatry 1984;141:1356-64.
11. Sano M, Ernesto C, Thomas RB. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Co-operative Study. New Engl J Med 1997;336:1216-22.
12. Kanowski S, Herrmann WM, Stephan K. Proof of efficacy of the gingko biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 1996;29:47-56.
13. Lamy PP. The role of cholinesterase inhibitors in Alzheimer's disease. CNS Drugs 1994;1:146-65.
14. Drachman DA, Glosser G, Flemming P. Memory decline in the aged: treatment with high doses of lecithin. Neurology 1981;31:101.
15. Wallace JD. Recent findings with cognitive enhancing drugs. Inpharma 1991;July 13, 12-13.
16. Eagger SA, Harvey RJ. Tacrine and other anticholinesterase drugs in dementia. Curr Opin Psychiatry 1995;8:264-7.
17. Qizilbash N, Birks J, Arrieta JL et al. The efficacy of tacrine in Alzheimer's disease, In: Beppu H, Huppert F, Kaye J et al. Dementia and cognitive module of the Cochrane database of systematic reviews. The Cochrane Collaboration; Issue 3. Oxford: Update Software; 1997.
18. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a multicentre, randomised, double blind, placebo controlled trial. Dementia 1996;7:293-303.
19. Lovestone S, Graham N, Howard R. Guidelines on drug treatment for Alzheimer's disease. Lancet 1997;350:232-3.
20. McKhann G, Drachman D, Flostein M et al. Clinical diagnosis of Akheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
21. Jones R, Comptoa S, Goddard C et al. On behalf of a working group of the Royal College of Psychiatrists. Interim statement on anti-dementia drugs: implications, concerns and policy proposals. Psychiatric Bull 1997;21:586-7.
22. Colenda CC Buspirone in treatment of agitated dementia patients. Lancet 1988;1:1169.
23. Hope RA, Patel V, Series H. Dexamphetamine may reduce hyperactivity in dementia - a case study using direct observation. Int J Geriatr Psychiatry 1991;6:165-9.
24. Goad DL, Davis C, Liem P, Fuselier CC, McCormack JR, Olson KM. The use of selegilene in Alzheimer's patients with behavioural problems. J Clin Psychiatry 1991;52:342-5.
25. Greenwald BS, Marin DB, Silverman SM. Serotonergic treatment of screaming and banging in dementia. Lancet 1986;2:1464-5.
26. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. BrJ Psychiatry 1990;157:894-901.
27. Magnus RV. A controlled trial of chlormethiazole in the management of symptoms of the organic dementias in the elderly. Clin Ther 1978;1:387-96.
28. Paton C, Procter AW. Carbamazepine use in a psychiatric hospital - an epidemiological study. J Pharm Med 1992;2:1-9.
29. Lee H, Cooney J, Lawlor B. The use of risperidone, an atypical neuroleptic, in Lewy body disease. Int J Geriatr Psychiatry 1994;9:415-7.
30. McShane R, Keene J, Gedling K, Fairburn C, Jacoby R, Hope T. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow-up. BMJ 1997;314:266-270.